A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer

详细信息    查看全文

• 作者：Adam Dickler ; Michael C. Kirk ; Alan Coon ; Damian Bernard ; Tom Zusag ; Jacob Rotmensch ; David E. Wazer
• 关键词：Xoft electronic brachytherapy ; Brachytherapy ; Endometrial cancer
• 刊名：Brachytherapy
• 出版年：2008
• 出版时间：October-December 2008
• 年：2008
• 卷：7
• 期：4
• 页码：351-354
• 全文大小：171 K

文摘

Purpose

This analysis was undertaken to dosimetrically compare iridium-192 high-dose-rate brachytherapy (IB) and Xoft Axxent Electronic Brachytherapy (XB; Xoft Inc., Sunnyvale, CA) in the treatment of endometrial cancer.

Methods and Materials

The planning CT scans from 11 patients previously treated with IB were used to construct hypothetical treatment plans using the source characteristics of the XB device. The mean V₉₅, V₁₀₀, and V₁₅₀ (percent of the planning target volume that received 95 % , 100 % , and 150 % of the prescription dose) were calculated. For both the bladder and rectum, the V₃₅ (percent of the organ that received 35 % of the prescription dose) and V₅₀ (percent of the organ that received 50 % of the prescription dose) were calculated for each patient using both methods of vaginal brachytherapy.

Results

The mean % V₉₅ was 99.7 % vs. 99.6 % (p = ns) and the mean % V₁₀₀ was 99.0 % vs. 99.1 % (p = ns) for the IB and XB methods, respectively. The mean % V₁₅₀ was 35.8 % vs. 58.9 % (p < 0.05) for the IB and XB methods, respectively. The mean bladder % V₃₅ was 47.7 % vs. 27.4 % (p < 0.05) and the mean bladder % V₅₀ was 26.5 % vs. 15.9 % (p < 0.05) for the IB and XB methods, respectively. The mean rectal % V₃₅ was 48.3 % vs. 28.3 % (p < 0.05) and the mean rectal % V₅₀ was 27.8 % vs. 17.0 % (p < 0.05) for the IB and XB methods, respectively.

Conclusions

The IB and XB methods of vaginal brachytherapy offer equivalent target volume coverage; however, the XB method allows increased sparing of the bladder and rectum.